БИБЛИОТЕКА
-
- Фильтр
- Количество записей: 3194
-
- По дате
- По просмотрам
-
Зарубежные материалы
High prevalence of previously unknown heart failure and left ventricular dysfunction in patients with type 2 diabetes
Aims/hypothesis The aim of this study was to assess the prevalence of (unknown) heart failure and left ventricular dysfunction in older patients with type 2 diabetes.
Подробнее1007
-
Зарубежные материалы
Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientifc evidence from across the world in 2007–2017
Te International Diabetes Federation (IDF) estimates that worldwide, 415 million people have diabetes, 91% of whom have type 2 diabetes mellitus (T2DM). People with diabetes comprise 8.8% of the world’s population, and IDF predicts that the number of cases of diabetes will rise to 642 million by 2040
Подробнее945
-
Статьи
Алгоритмы специализированной медицинской помощи больным сахарным диабетом (9-й выпуск)
Данное издание содержит восьмой актуализированный выпуск клинических рекомендаций по стандартизации и оптимизации оказания медицинской помощи больным сахарным диабетом во всех регионах России на основе доказательной медицины.
Подробнее1186
-
Зарубежные материалы
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
The effects of empagliflozin, an inhibitor of sodium–glucose cotransporter 2, in addition to standard care, on cardiovascular morbidity and mortality in patients with type 2 diabetes at high cardiovascular risk are not known.
Подробнее932
-
Зарубежные материалы
Type 2 diabetes and cardiovascular disease: Have all risk factors the same strength?
Diabetes mellitus is a chronic condition that occurs when the body cannot produce enough or effectively use of insulin. Compared with individuals without diabetes, patients with type 2 diabetes mellitus have a considerably higher risk of cardiovascular morbidity and mortality, and are disproportionately affected by cardiovascular disease.
Подробнее969
-
Зарубежные материалы
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (The new england journal of medicine)
The cardiovascular effect of liraglutide, a glucagon-like peptide 1 analogue, when added to standard care in patients with type 2 diabetes, remains unknown.
Подробнее740
-
Статьи
Инициация терапии сахарного диабета 2 типа: новые возможности
В настоящее время сахарный диабет (СД) 2 типа является глобальной проблемой здравоохранения – распространенность патологии достигла масштабов эпидемии как в развитых, так и развивающихся странах
Подробнее834
-
Зарубежные материалы
Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
The cardiovascular effects of adding once-weekly treatment with exenatide to usual care in patients with type 2 diabetes are unknown.
Подробнее731
-
Зарубежные материалы
Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients
Lorcaserin, a selective serotonin 2C receptor agonist that modulates appetite, has proven efficacy for weight management in overweight or obese patients. The cardiovascular safety and efficacy of lorcaserin are undefined.
Подробнее806
-
Статьи
Артериальная гипертензия у взрослых
Артериальная гипертензия (АГ) — синдром повышения клинического артериального давления (АД) при гипертонической болезни и симптоматических АГ выше пороговых значений, определенных в результате эпидемиологических и рандомизированных контролируемых исследований, продемонстрировавших связь с повышением сердечнососудистого риска и целесообразность и пользу лечения, направленного на снижение АД ниже ...
Подробнее1167
-
Зарубежные материалы
Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus
Abstract—The American Heart Association (AHA) and the American Diabetes Association (ADA) have each published guidelines for cardiovascular disease prevention: The ADA has issued separate recommendations for each of the cardiovascular risk factors in patients with diabetes, and the AHA has shaped primary and secondary guidelines that extend to patients with diabetes. This statement will attempt to ...
Подробнее888
-
Зарубежные материалы
Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus
In DECLARE-TIMI 58 (Dapagliflozin Effect on Cardiovascular Events–Thrombolysis in Myocardial Infarction 58), the sodium-glucose cotransporter 2 inhibitor dapagliflozin reduced the composite end point of cardiovascular death/hospitalization for heart failure (HHF) in a broad population of patients with type 2 diabetes mellitus. However, the impact of baseline left ventricular ejection fraction (EF) ...
Подробнее898
-
Зарубежные материалы
Kidney Disease as a Risk Factor for Development of Cardiovascular Disease
A Statement From the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention
Подробнее1093
-
Зарубежные материалы
Obesity and Diabetic Kidney Disease
The prevalence of obesity (body mass index, BMI ≥ 30 kg/m2) has risen to epidemic proportions and continues to be a major health problem worldwide 1–3. The high prevalence of obesity is closely linked to the increased incidence of a number of chronic diseases, including type 2 diabetes, hypertension and cardiovascular disease 2, 4–8.
Подробнее1158
-
Зарубежные материалы
Diabetes with early kidney involvement may shorten life expectancy by 16 years
This study aimed to identify the excess risks associated with diabetic patients with early kidney involvement (early diabetic kidney disease). The mortality risks of early diabetic kidney disease, defined as diabetes in early stages 1-3 chronic kidney disease (CKD), were assessed from a cohort of 512,700 adults in Taiwan participating in a health surveillance program from 1994-2008. Three related ...
Подробнее1270
- ← Предыдущая
- 1
- ...
- 125
- 126
- 127
- 128 (current)
- 129
- 130
- 131
- ...
- 213
- Следующая →